Aug 27, 2026 03:29PM
Aug 27, 2026 03:29PM
Aug 27, 2026 03:29PM
Aug 27, 2026 03:28PM
Aug 27, 2026 03:28PM
Aug 27, 2026 03:28PM
Aug 6, 2026 07:00AM Priovant enrolls first patients in Phase 3 cutaneous sarcoidosis trial
Aug 6, 2026 07:00AM
Aug 6, 2026 07:00AM
Jul 23, 2026 04:05PM
May 21, 2026 09:17AM
May 21, 2026 06:20AM
May 20, 2026 07:00AM
Apr 2, 2026 05:00AM Priovant begins phase 2b/3 trial for brepocitinib in rare scalp disorder
Apr 2, 2026 05:00AM
Apr 2, 2026 05:00AM
Apr 2, 2026 05:00AM
Mar 28, 2026 03:00PM
Mar 28, 2026 03:00PM
Mar 3, 2026 07:00AM
Mar 3, 2026 07:00AM Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis
Feb 10, 2026 06:52AM
Feb 6, 2026 07:00AM
Feb 6, 2026 07:00AM
Feb 6, 2026 07:00AM
Feb 6, 2026 07:00AM
Oct 1, 2025 01:20PM
Oct 1, 2025 01:13PM FDA on Operations During Shutdown: 'FDA will not be able to accept any regulatory submissions for FY 2026 that require a fee payment'
Sep 3, 2025 01:01PM
Sep 3, 2025 01:01PM
Apr 21, 2025 07:02AM
Apr 21, 2025 07:00AM
Nov 12, 2024 07:00AM
Oct 28, 2024 09:25AM
Oct 28, 2024 09:25AM Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
Sep 18, 2024 07:30AM
Sep 18, 2024 07:30AM
Sep 11, 2024 06:36AM
Sep 9, 2024 07:02AM
Sep 9, 2024 07:00AM
Aug 8, 2024 07:00AM
May 30, 2024 07:00AM Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update
Feb 13, 2024 07:00AM
Nov 13, 2023 07:00AM
Nov 10, 2023 08:03AM
Nov 10, 2023 08:00AM
Aug 14, 2023 07:00AM
Jul 11, 2023 08:00AM
Jun 28, 2023 08:57AM UPDATE -- Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update
Jun 28, 2023 07:00AM

330,005 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All